WORLDREMIT
14.9.2020 13:11:06 CEST | Business Wire | Press release
Lonestar Cell MTN, Liberia’s leading GSM and Mobile Financial Services company, has partnered with WorldRemit to make it possible for Mobile Money customers to now receive international remittances straight to their Lonestar Cell MTN Mobile Money accounts, free of charge.
This service presents the exciting prospect for the Liberian community to receive seamless international remittances from their family and friends, anywhere in Europe, Canada and the USA.
Now, with over 7,000 Lonestar Cell MTN cashpoint locations across Liberia, the service eliminates the stress, risks and long queues in banking halls associated with receiving remittances sent by loved ones. In addition to the MoMo services which has a vast and rapidly expanding MoMo ecosystem, using MoMo for international remittances and daily financial transactions makes life easier, safer and more convenient.
Christopher Ssali, Acting General Manager of Lonestar Cell MTN Mobile Money, said, “Liberians can now receive international financial remittances from family and friends in Europe, Canada and the USA more easily and safely. We have seen how resilient the people of Liberia truly are and we are very proud to be at the forefront of innovative technologies and partnerships which can help Liberians live convenient lives. Our partnership with WorldRemit does just that. Our MoMo ecosystem has grown so customers can use the money they receive to pay bills, buy goods, and pay for the services they need with Mobile Money. We are excited about this because it makes our customers lives easier and we are supporting the government’s aim for a cashless digital economy and financial inclusion.”
Awa Gueye Ba, Head of Francophone West & Central Africa at WorldRemit, remarked that this partnership with Lonestar Cell MTN provides increased opportunities for customers to connect with their loved ones and receive convenient money transfers. “The MoMo service is one of the most demanded services in Liberia and we are excited about this collaboration with MTN Liberia, as it will allow users to send remittances 24/7 from the WorldRemit website or mobile app and receive directly to their MTN Mobile Money accounts. The partnership will further strengthen the efforts of the Central Bank of Liberia in focusing on diverse means of delivering financial services to the rural community sector of the population and integrating them into the formal economy.
Providing our customers with safe, convenient and fast means to receive money is an important step towards WorldRemit’s ambition to support customers, in the shift towards the digital economy.”
Customers who receive money can conveniently cashout, pay goods and services, or transfer the money to their friends and family at the prevailing standard Mobile Money fees. Customers who are not on MTN Mobile Money can join easily. Sign up is free. All they need to do is visit any Lonestar Cell MTN service center or registered MoMo agent with a valid identification card and fill out an application form.
We are #GoodTogether .
About Lonestar Cell MTN/MTN Liberia
Lonestar Cell MTN/MTN Liberia, Liberia’s leading telecommunications provider, was founded in 2001. We are a technology-based company with a focus on winning in everything we do while demonstrating consistency in innovation to meet our unique customer needs. We are a subsidiary of MTN, a leading international telecommunications groups operating in 21 countries across Africa and the Middle East.
For more information, please visit www.lonestarcell.com
About WorldRemit
WorldRemit is a leading global payments company. We disrupted an industry previously dominated by offline legacy players by taking international money transfers online - making them safer, faster and lower-cost. We currently send from 50 to 150 countries, operate in 6,500 money transfer corridors worldwide and employ over 1,100 people globally.
On the sending side WorldRemit is 100% digital (cashless), increasing convenience and enhancing security. For those receiving money, the company offers a wide range of options including bank deposit, cash collection, mobile airtime top-up and mobile money.
Backed by Accel, TCV and Leapfrog – WorldRemit’s headquarters are in London, United Kingdom with regional offices in the United States, Canada, Australia, New Zealand, Hong Kong, Singapore, Malaysia, the Philippines, South Africa, Somaliland, Uganda, Kenya, Rwanda, Tanzania, Zimbabwe and Belgium.
For more information visit www.worldremit.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom